These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35417176)

  • 1. Spray-Dried Monoclonal Antibody Suspension for High-Concentration and Low-Viscosity Subcutaneous Injection.
    Huang C; Chen L; Franzen L; Anderski J; Qian F
    Mol Pharm; 2022 May; 19(5):1505-1514. PubMed ID: 35417176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying-the Road to Manufacturing Scale.
    Gikanga B; Turok R; Hui A; Bowen M; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2015; 69(1):59-73. PubMed ID: 25691715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection.
    Bowen M; Armstrong N; Maa YF
    J Pharm Sci; 2012 Dec; 101(12):4433-43. PubMed ID: 23001898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulating monoclonal antibodies as powders for reconstitution at high concentration using spray-drying: Trehalose/amino acid combinations as reconstitution time reducing and stability improving formulations.
    Massant J; Fleurime S; Batens M; Vanhaerents H; Van den Mooter G
    Eur J Pharm Biopharm; 2020 Nov; 156():131-142. PubMed ID: 32882422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulating monoclonal antibodies as powders for reconstitution at high concentration using spray drying: Models and pitfalls.
    Batens M; Massant J; Teodorescu B; Van den Mooter G
    Eur J Pharm Biopharm; 2018 Jun; 127():407-422. PubMed ID: 29499299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Product Characterization of High Concentration Non-Aqueous Protein Powder Suspensions.
    Marschall C; Witt M; Hauptmeier B; Frieß W
    J Pharm Sci; 2023 Jan; 112(1):61-75. PubMed ID: 35779665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Powder suspensions in non-aqueous vehicles for delivery of therapeutic proteins.
    Marschall C; Witt M; Hauptmeier B; Friess W
    Eur J Pharm Biopharm; 2021 Apr; 161():37-49. PubMed ID: 33548460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrostatic spray drying for monoclonal antibody formulation.
    Mutukuri TT; Maa YF; Gikanga B; Sakhnovsky R; Zhou QT
    Int J Pharm; 2021 Sep; 607():120942. PubMed ID: 34324986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spray drying lactose from organic solvent suspensions for aerosol delivery to the lungs.
    Ke WR; Chang RYK; Kwok PCL; Chen D; Chan HK
    Int J Pharm; 2020 Dec; 591():119984. PubMed ID: 33069893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Strategies in Development and Manufacturing of Low Viscosity, Ultra-High Concentration Formulation for IgG1 Antibody.
    Deokar V; Sharma A; Mody R; Volety SM
    J Pharm Sci; 2020 Dec; 109(12):3579-3589. PubMed ID: 32946895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viscosity-Lowering Effect of Amino Acids and Salts on Highly Concentrated Solutions of Two IgG1 Monoclonal Antibodies.
    Wang S; Zhang N; Hu T; Dai W; Feng X; Zhang X; Qian F
    Mol Pharm; 2015 Dec; 12(12):4478-87. PubMed ID: 26528726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High concentration formulation feasibility of human immunoglubulin G for subcutaneous administration.
    Dani B; Platz R; Tzannis ST
    J Pharm Sci; 2007 Jun; 96(6):1504-17. PubMed ID: 17387698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of high concentration protein powder suspensions by milling of lyophilizates.
    Marschall C; Graf G; Witt M; Hauptmeier B; Friess W
    Eur J Pharm Biopharm; 2021 Sep; 166():75-86. PubMed ID: 34058328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Stability Constraints in the Particle Engineering of an Inhaled Monoclonal Antibody Dried Powder.
    Brunaugh AD; Ding L; Wu T; Schneider M; Khalaf R; Smyth HDC
    J Pharm Sci; 2022 Feb; 111(2):403-416. PubMed ID: 34453927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.
    Schüle S; Friess W; Bechtold-Peters K; Garidel P
    Eur J Pharm Biopharm; 2007 Jan; 65(1):1-9. PubMed ID: 17034996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of drying method and formulation on the physical properties and stability of methionyl human growth hormone in the amorphous solid state.
    Abdul-Fattah AM; Lechuga-Ballesteros D; Kalonia DS; Pikal MJ
    J Pharm Sci; 2008 Jan; 97(1):163-84. PubMed ID: 17722086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing freeze drying and spray drying of interleukins using model protein CXCL8 and its variants.
    Fiedler D; Hartl S; Gerlza T; Trojacher C; Kungl A; Khinast J; Roblegg E
    Eur J Pharm Biopharm; 2021 Nov; 168():152-165. PubMed ID: 34474111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-spray dried hydrophobic drug formulations with crystalline lactose for inhalation aerosol delivery.
    Ke WR; Kwok PCL; Khanal D; Chang RYK; Chan HK
    Int J Pharm; 2021 Jun; 602():120608. PubMed ID: 33862136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spray-dried microparticles containing polymeric nanocapsules: formulation aspects, liquid phase interactions and particles characteristics.
    Tewa-Tagne P; Briançon S; Fessi H
    Int J Pharm; 2006 Nov; 325(1-2):63-74. PubMed ID: 16872767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caffeine as a Viscosity Reducer for Highly Concentrated Monoclonal Antibody Solutions.
    Zeng Y; Tran T; Wuthrich P; Naik S; Davagnino J; Greene DG; Mahoney RP; Soane DS
    J Pharm Sci; 2021 Nov; 110(11):3594-3604. PubMed ID: 34181992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.